Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | PDE4A | P27815 | 5/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | FSHR | P23945 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423912 | 0.91 | LHCGR (0.56) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL5034065 | 0.90 | LHCGR (0.67) | LHCGRTSHRHTR2AFSHR | |
| SCHEMBL4430406 | 0.90 | LHCGR (0.58) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL4426360 | 0.82 | LHCGR (0.63) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL4433012 | 0.82 | LHCGR (0.67) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL4906981 | 0.82 | LHCGR (0.56) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL4431550 | 0.82 | LHCGR (0.57) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL5140326 | 0.81 | LHCGR (0.73) | LHCGRTSHRBRAFPDE4APDE4B | |
| SCHEMBL5038376 | 0.80 | LHCGR (0.75) | LHCGRTSHRFSHR | |
| SCHEMBL4420434 | 0.80 | LHCGR (0.51) | LHCGRTSHRBRAFPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 13/4885TSHR 1000/4885BRAF 4474/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 10/4885TSHR 517/4885BRAF 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.